LivaNova PLC

LIVN Healthcare Medical Devices

LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.8%, EPS grew 296.0%, free cash flow fell 26.7% and total debt fell 31.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

77.60 0.90 −1.15%
Market cap
$4.3B
P/E
22.5×
Fwd P/E
26.0×
Dividend yield
—
F-score
4/9
Altman Z
1.74
Beneish M
−3.30
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 32.26 23.83
P/S ratio
2.12 2.42 2.42 3.07
P/FCF ratio
15.21 18.94 21.07 29.69
P/Operating CF
33.64 40.73 228.44 67.88
P/B ratio
2.47 2.80 2.87 3.41
EV/Sales
1.96 2.23 2.25 2.92
EV/EBITDA
9.65 10.98 11.73 15.76
EV/FCF
14.08 17.48 19.54 28.23
Current Ratio
1.33 1.36 1.33 1.45
Net Debt/EBITDA
(2.82) (4.10) (4.07) (3.07)
Debt/Equity
0.38 0.31 0.24 0.22
Earnings Yield
(7.62%) (7.23%) 3.10% 4.20%
Free Cash Flow Yield
6.58% 5.28% 4.75% 3.37%
Free Cash Flow per Share
1.14 1.05 0.02 0.64
Book value per Share
21.18 22.00 22.15 24.11
Free Cash Flow
62.18 57.45 0.93 35.04
EV/EBIT
13.67 15.53 16.77 22.91
Other line items

Show all line items

Columns are period end dates